Dr. Sean Zeng is Senior Manager, Cross-sector Innovation Collaboration at Merck Innovation Hub China. He is responsible for technology foresight and scouting for Merck Innovation Fields including Liquid Biopsy Technologies. Before joining Merck, Dr. Zeng worked at GSK and J&J China R&D with business development and external alliance roles. He holds a bachelor's degree in Biotechnology from Peking University and a PhD degree in Neuroscience from Chinese Academy of Sciences.
Dr. Shichun Tu is CEO of Huidu (Shanghai) Medical Sciences and holds a Ph.D. from T.H. Morgan School of Biological Sciences, University of Kentucky, has served as assistant professor at Sanford Burnham Medical Research Institute, Adjunct Professor at Scintillon Institute, Senior Scientist and Director of Neural Degeneration Department at Allele Biotechnology, and CTO & Director of Medical & R&D at Shanghai RightOn Biotechnology. Dr. Tu received the research fund issued by NIH of the National Health Ministry four times. The research has been published in international professional journals such as Nature, Neuron and PNAS.
Dr. Qihui Shi is a professor of Fudan University Shanghai Medical College since summer of 2018. Before joining faculty of Fudan University, Dr. Shi is a professor of Shanghai Center for Systems Biomedicine at Shanghai Jiao Tong University from September 2011 to June 2018. Dr. Shi received his B.S. from Fudan University and a Ph.D. in Chemistry from University of California, Santa Barbara. Dr. Shi conducted his postdoc research at Caltech. His research interests are centered on developing new technologies in cell-based liquid biopsy.
涂士春博士现任慧渡（上海）医疗科技有限公司CEO。涂士春博士毕业于美国肯塔基大学生物系，在美国Sanford Burnham Medical Research Institute、Scintillon Institute、美国Allele生物技术医药有限公司和上海睿昂生物技术有限公司先后担任助理教授、客座教授、疾病研究部主任、医学研发总监和首席技术官。涂士春博士四次获得美国国家卫生部NIH颁发的研究基金，科研成果发表在Nature, Neuron, PNAS等国际专业杂志。